cas 1289942-66-0|| where to buy 2-((3-Fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methylpropanoic acid

Nom du produit:2-((3-Fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methylpropanoic acid

IUPAC Name:2-{[3-fluoro-4-(methylcarbamoyl)phenyl]amino}-2-methylpropanoic acid

Unité d'emballage	Stock disponible	Prix($)
CM248707-500g	in stock	ũƿƿ
CM248707-1000g	in stock	ưǜǜ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1289942-66-0 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1289942-66-0; Formule moléculaire:C12H15FN2O3; Point de fusion:-; Code SMILES:CC(C)(NC1=CC=C(C(NC)=O)C(F)=C1)C(O)=O; Densité:

: Numéro de catalogue:CM248707; Poids moléculaire:254.26; Point d'ébullition:455.1°C at 760 mmHg; N° Mdl:MFCD22581651; Stockage:Store at 2-8°C.

: Amino Acids and Peptides; Amino acids are organic compounds containing a basic amino group and an acidic carboxyl group. Because amino acids contain both amino and carboxyl groups, they can be polymerized in an end-to-end manner, removing a molecule of water to form a covalent amide bond or peptide bond. Many amino acids are linked together end to end to form a polypeptide. Amino acids and peptides are important components in the fields of medicine and life sciences.; amino acids wholesale; if you are finding amino acids wholesaler in china, we will be your best choose! We have our own factory, so we can give you a cheap price!

: Enzalutamide; Aug. 23, 2023, FDA grants priority review for XTANDI(enzalutamide) in non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.
XTANDI (enzalutamide) is an androgen receptor signaling inhibitor. Androgen receptor inhibitors interfere with the connection between androgens and androgen receptors. This can help slow cancer cell growth.XTANDI is currently approved for one or more of these indications in more than 100 countries, including in the U.S., European Union and Japan. Over one million patients have been treated with XTANDI globally.